Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies

Andrea Koch, Emilio Pizzichini, Alan Hamilton, Lorna Hart, Lawrence Korducki, Maria Cristina De Salvo, Pierluigi Paggiaro, Andrea Koch, Emilio Pizzichini, Alan Hamilton, Lorna Hart, Lawrence Korducki, Maria Cristina De Salvo, Pierluigi Paggiaro

Abstract

Two replicate, multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase III studies investigated the long-term efficacy and safety of once-daily olodaterol via Respimat® versus placebo and formoterol over 48 weeks in patients with moderate to very severe chronic obstructive pulmonary disease receiving usual-care background therapy. Patients received once-daily olodaterol 5 or 10 μg, twice-daily formoterol 12 μg, or placebo. Co-primary end points were forced expiratory volume in 1 second (FEV1) area under the curve from 0-3 hours response, FEV1 trough response, and Mahler transition dyspnea index total score after 24 weeks; secondary end points included St George's Respiratory Questionnaire. Overall, 904 (Study 1222.13) and 934 (Study 1222.14) patients received treatment. Olodaterol significantly improved FEV1 area under the curve from 0-3 hours versus placebo in both studies (with olodaterol 5 μg, 0.151 L and 0.129 L; with olodaterol 10 μg, 0.165 L and 0.154 L; for all comparisons P<0.0001) and FEV1 trough responses versus placebo (0.053-0.085 L; P<0.01), as did formoterol. Primary analysis revealed no significant difference in transition dyspnea index focal score for any active treatment versus placebo. Post hoc analysis using pattern mixture modeling (accounting for discontinuations) demonstrated statistical significance for olodaterol versus placebo. St George's Respiratory Questionnaire total score was significantly improved with olodaterol, but not formoterol, versus placebo. No safety signals were identified from adverse-event or other safety data. Once-daily olodaterol 5 μg and 10 μg is efficacious in patients with moderate to very severe chronic obstructive pulmonary disease on usual-care maintenance therapy, with a satisfactory safety profile.

Trial registration: ClinicalTrials.gov NCT00793624 NCT00796653.

Keywords: bronchodilator; chronic obstructive pulmonary disease; dyspnea; long-acting beta2-agonist.

Figures

Figure 1
Figure 1
Studies 1222.13 and 1222.14 study design. Abbreviations: QD, once daily; BID, twice daily.
Figure 2
Figure 2
CONSORT diagram illustrating participant flow in Study 1222.13 (A) and Study 1222.14 (B). Notes:aOne patient withdrew consent prior to dosing; one patient withdrawn due to inability to perform spirometry; bincludes two patients who were randomized and withdrew consent prior to receiving study medication. Abbreviations: QD, once daily; FEV1, forced expiratory volume in 1 second; AUC0–3, area under the curve from 0–3 hours; CONSORT, Consolidated Standards of Reporting Trials.
Figure 3
Figure 3
Adjusted mean TDI focal score over 48 weeks of treatment. Notes: Combined data set based on an MMRM (A) and a PMM model (B); and individual data from Study 1222.13 (C) and Study 1222.14 (D). Abbreviations: MMRM, mixed model for repeated measurements; TDI, transition dyspnea index; PMM, pattern mixture modeling.

References

    1. Global Initiative for Chronic Obstructive Lung Disease Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Updated 2013. [Accessed July 15, 2013]. Available from: .
    1. Hanania NA, Donohue JF. Pharmacologic interventions in chronic obstructive pulmonary disease. Bronchodilators. Proc Am Thorac Soc. 2007;4(7):526–534.
    1. Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2- adrenoceptor agonist bronchodilator. Life Sci. 1993;52(26):2145–2160.
    1. Ball DI, Brittain RT, Coleman RA, et al. Salmeterol, a novel, long-acting β2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol. 1991;104(3):665–671.
    1. Maesen FPV, Smeets JJ, Sledsens TJH, Wald FDM, Cornelissen PJG, Dutch study group Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD) Eur Respir J. 1995;8(9):1506–1513.
    1. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1136–1142.
    1. Bauwens O, Ninane V, Van de Maele B, et al. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin. 2009;25(2):463–470.
    1. Rau JL. Determinants of patient adherence to an aerosol regimen. Respir Care. 2005;50(10):1346–1356.
    1. Rodrigo GJ, Neffen H. Comparison of indacaterol with tiotropium or twice-daily long-acting β-agonists for stable COPD: a systematic review. Chest. 2012;142(5):1104–1110.
    1. Bouyssou T, Casarosa P, Naline E, et al. Pharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010;334(1):53–62.
    1. Casarosa P, Kollak I, Kiechle T, et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther. 2011;337(3):600–609.
    1. van Noord JA, Smeets JJ, Drenth BM, et al. 24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPD. Pulm Pharmacol Ther. 2011;24(6):666–672.
    1. O’Byrne PM, van der Linde J, Cockcroft DW, et al. Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting β2-agonist, in patients with mild asthma. J Allergy Clin Immunol. 2009;124(6):1217–1221.
    1. van Noord JA, Korducki L, Hamilton A, Koker P. Four weeks once daily treatment with BI 1744 CL, a novel long-acting β2-agonist, is effective in COPD patients. Am J Respir Crit Care Med. 2009;179:A6183. (abstract)
    1. Joos G, Aumann JL, Coeck C, Korducki L, Hamilton AL, van Noord J. Comparison of 24-hour FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with COPD. Am J Respir Crit Care Med. 2012;185:A2930. (abstract)
    1. O’Byrne PM, D’Urzo T, Gahlemann M, Hart L, Wang F, Beck E. Dose-finding study of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma. Am J Respir Crit Care Med. 2012;185:A3963. (abstract)
    1. European Medicines Agency Guideline on Clinical Investigation of Medicinal Products in the Treatment of Chronic Obstructive Pulmonary Disease (COPD) [Accessed August 7, 2013]. Available from: .
    1. Mahler DA. Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(3):234–238.
    1. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85(6):751–758.
    1. Jones PW, Quirk FH, Baveystock CM. The St. George’s Respiratory Questionnaire. Resp Med. 1991;85(Suppl B):25–31.
    1. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338.
    1. Siddiqui O, Hung HM, O’Neill R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 36 NDA datasets. J Biopharm Stat. 2009;19(2):227–246.
    1. Little RJ, Wang Y. Pattern-mixture models for multivariate incomplete data with covariates. Biometrics. 1996;52(1):98–111.
    1. Panel on Handling Missing Data in Clinical Trials, Committee on National Statistics, Division of Behavioral and Social Sciences and Education, National Research Council . The Prevention and Treatment of Missing Data in Clinical Trials. Washington DC: National Academies Press; 2010.
    1. Hogan JW, Roy J, Korkontzelou C. Handling drop-out in longitudinal studies. Stat Med. 2004;23(9):1455–1497.
    1. Ichinose M, Takizawa A, Izumoto T, Fukuchi Y. Efficacy of 4 weeks’ once-daily treatment with olodaterol (BI 1744), a novel long-acting β2-agonist, in Japanese patients with COPD. Am J Respir Crit Care Med. 2012;185:A2931. (abstract)
    1. Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Two 48-week studies. Eur Respir J. 2013;42( Suppl 57):146s–P764. (abstract)
    1. Ferguson G, Feldman G, Hofbauer P, et al. Lung function efficacy of olodaterol QD delivered via Respimat® in COPD patients: Results from two 48-week studies. Eur Respir J. 2013;42( Suppl 57):5s–187. (abstract)
    1. Lange P, Aumann J-L, Derom E, et al. The 24-h FEV1 time profile of olodaterol QD delivered via Respimat® in COPD: Results from two 6-week studies. Eur Respir J. 2013;42(Suppl 57):982s–4635. (abstract)
    1. McGarvey L, Koch A, Sachs P, et al. 48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis. Eur Respir J. 2013;42(Suppl 57):749s–P3633. (abstract)
    1. Joos G, Aumann JL, Coeck C, Korducki L, Hamilton AL, van Noord JA. Comparison of 24-hour FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2agonist, in patients with COPD; Poster A2930 presented at the 103rd Annual International Conference of the American Thoracic Society; San Francisco, CA, USA. May 18–23, 2012.
    1. Feldman G, Bernstein J, Hamilton A, Nivens C, Wang F, LaForce C. The 24-hour FEV1 time profile of olodaterol once daily (QD) via Respimat® and formoterol twice daily (BID) via Aerolizer® in patients with COPD: results from two 6-week studies; Abstract 749A presented at CHEST; Chicago, IL, USA. October 26–31, 2013.
    1. Koch A, Paggiaro P, Hamilton A, et al. Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Combined analysis from two 48-week studies. Eur Respir J. 2013;42(Suppl 57):145s–P763. (abstract)
    1. Maltais F, Kirsten A, Hamilton A, De Sousa D, Wang F, Decramer M. Evaluation of the effects of olodaterol on exercise endurance in patients with COPD: results from two 6-week studies; Abstract 748A presented at CHEST; Chicago, IL, USA. October 26–31, 2013.
    1. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14:49.
    1. Bouyssou T, Schnapp A, Casarosa P, Pieper MP. Addition of the new once-daily LABA BI 1744 to tiotropium results in superior bronchoprotection in pre-clinical models. Am J Respir Crit Care Med. 2010;181:A4445. (abstract)
    1. Bouyssou T, Casarosa P, Pieper M, Schnapp A, Gantner F. Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs. Eur Respir J. 2011;38(Suppl 55):613s–3451. (abstract)
    1. Maltais F, Beck E, Webster D, et al. Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients. Eur Respir J. 2010;36(Suppl 54):1014s–5557. (abstract)
    1. Aalbers R, Maleki-Yazdi MR, Hamilton A, et al. Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD; Abstract 2882 presented at the European Respiratory Society Annual Congress; Vienna, Austria. September 1–5, 2012.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner